Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBT (2016 - 2025)

Historic EBT for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Altimmune's EBT rose 1676.95% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year increase of 1816.65%. This contributed to the annual value of -$95.1 million for FY2024, which is 752.99% down from last year.
  • Altimmune's EBT amounted to -$19.0 million in Q3 2025, which was up 1676.95% from -$22.1 million recorded in Q2 2025.
  • Altimmune's EBT's 5-year high stood at -$14.9 million during Q1 2021, with a 5-year trough of -$33.5 million in Q3 2021.
  • Moreover, its 5-year median value for EBT was -$22.1 million (2025), whereas its average is -$22.5 million.
  • As far as peak fluctuations go, Altimmune's EBT tumbled by 12259.34% in 2021, and later surged by 2923.6% in 2022.
  • Quarter analysis of 5 years shows Altimmune's EBT stood at -$23.9 million in 2021, then rose by 9.33% to -$21.7 million in 2022, then plummeted by 46.08% to -$31.6 million in 2023, then grew by 26.37% to -$23.3 million in 2024, then increased by 18.39% to -$19.0 million in 2025.
  • Its last three reported values are -$19.0 million in Q3 2025, -$22.1 million for Q2 2025, and -$20.3 million during Q1 2025.